Anti PD-L1 antibody: is there a histologic-oriented efficacy? Focus on atezolizumab in squamous cell non-small cell lung cancer

Anti PD-L1 antibody: is there a histologic-oriented efficacy? Focus on atezolizumab in squamous cell non-small cell lung cancer

Squamous cell lung cancer (SqCLC) is the second most common histotype of non-small cell lung cancer (NSCLC) and is characterized by severe prognosis and lack of specific target agents. Atezolizumab is the first anti Programmed Death Ligand-1 (PDL-1) inhibitor approved for NSCLC patients of both hist...

Full description

Bibliographic Details
Main Authors: Maria Gemelli, Paolo Bidoli, Francesca Colonese, Stefania Canova, Diego Cortinovis
Format: Article
Language:English
Published: IMR Press 2021-12-01
Series:Frontiers in Bioscience-Scholar
Subjects:
immune check point inhibitors
squamous non-small cell lung cancer
first-line therapy
advanced setting
neo-adjuvant setting
Online Access:https://www.imrpress.com/journal/FBS/13/2/10.52586/S562

Internet

https://www.imrpress.com/journal/FBS/13/2/10.52586/S562

Similar Items